Pierre Fabre S.a.

Pierre Fabre Medicament

Jacques Durand

Gerard Normier

Anne-Marie Pinel

Lucien D D'Hinterland

Lucien Dussourd d'Hinterland

Alain Le Pape

Lucien Dussourdd'Hinterland

Lucien Pradayrol

The present invention relates to an aerosol composition containing a carrier agent capable of recognizing and binding to inflammatory and tumor foci mobilizing macrophages in their immediate environment, and an aerosol substrate, characterized in that the said carrier agent consists of a polysaccharide compound selected from the compound D 25, extracted from the membrane proteoglycans of the bacterium Klebsiella pneumoniae and having a molecular weight of 30.+-.0.10 Kd, and the compound oxidized D 25 in which the galactofuranoser residue (Gal.sub.f) of the linear polysaccharide chain of D 25 has been converted to arabinose, and their amide, ester or ether type derivatives, as well as their quaternary ammonium derivatives and salts, and also the derivatives obtained by grafting of phosphatides.

Method for detecting and locating inflammatory or tumor foci in a

The present invention relates to a vaccinal complex containing a specific antigen. This is a vaccinal complex characterized in that it is composed of bacterial ribosomal RNA or fragments of bacterial ribosomal RNA on which are coupled from 1 to 5% by weight of a specific antigen of bacterial serotype. This complex may be used as a vaccine.

Vaccinal complex containing a specific antigen and vaccine containing it

This invention relates to a process for the preparation of purified bacterial membranal proteoglycans. The process comprises at least one step in which crude proteoglycans are treated in aqueous medium with a base or a hypobromite, followed by elimination of the excess reactant and the insoluble residue, the purified proteoglycans being present in aqueous solution. The thus obtained purified proteoglycans may be used as immunity adjuvants in vaccines without causing side-effects such as pyrogenic reactions.

Preparations of purified bacterial membranal proteoglycans

Immunostimulating preparations based on ribosomal RNA's and a process

Process for the preparation of purified bacterial membranal proteoglycans

The present invention relates to a pharmaceutical composition comprising a plasminogen activator and a polysaccharide sulphate. The invention also covers a process for preparing the pharmaceutical composition and a process for preparing the plasminogen activator. The pharmaceutical compositions are useful in the treatment of circulatory disorders such as venous thromboses.

Plasminogen activator pharmaceutical compositions

Growing community of inventors

Castres, France

Jacques Durand